Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score
Charlie Gourley(Edinburgh Cancer Research), E.A. Harrington, Tim French, Paul DiSilvestro(Women & Infants Hospital of Rhode Island), J. Carl Barrett(National Institute of Environmental Health Sciences), Jessica Brown(Children's Hospital of Orange County), Tsveta Milenkova(AstraZeneca (United Kingdom)), Hannah McGarvey, Cathy E. Elks(AstraZeneca (United Kingdom)), Pierre Lao‐Sirieix(Autolus (United Kingdom)), Kathleen N. Moore(University of Oklahoma Medical Center), Philip Rowe(University of Strathclyde), Ralph Bloomfield(AstraZeneca (United Kingdom)), Darren Hodgson(AstraZeneca (United Kingdom)), Zhongwu Lai(AstraZeneca (United States))
Cited by 7
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k